Free Trial

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$68.89
+2.3%
$71.10
$62.04
$87.77
$6.39B1.311.11 million shs1.55 million shs
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$105.56
-0.8%
$97.41
$43.89
$111.02
$6.61B0.65527,932 shs631,490 shs
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$121.24
+2.3%
$119.23
$87.14
$127.57
$6.90B0.95220,771 shs444,575 shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$81.68
+3.2%
$79.53
$54.09
$84.49
$7.11B0.55519,384 shs1.25 million shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
0.00%+8.35%+3.24%-17.98%-2.46%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.00%+2.67%-1.35%+10.98%+86.77%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.00%+0.90%+4.02%-0.54%+36.82%
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.00%+3.04%+2.42%+0.78%+49.05%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
4.623 of 5 stars
4.32.00.05.03.20.81.3
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.5202 of 5 stars
2.32.00.00.01.50.80.6
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
4.1202 of 5 stars
1.40.03.34.83.62.52.5
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.7526 of 5 stars
3.52.00.00.02.92.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.67
Moderate Buy$87.5627.09% Upside
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
2.53
Moderate Buy$103.94-1.54% Downside
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
2.80
Moderate Buy$124.602.77% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$96.1717.74% Upside

Current Analyst Ratings

Latest ACHC, HQY, ENSG, and BPMC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/22/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$94.00
5/17/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$101.00 ➝ $91.00
5/15/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
5/14/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$140.00
5/6/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform
5/6/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$121.00 ➝ $168.00
5/6/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeUnderperform ➝ Market Perform$50.00 ➝ $97.00
5/6/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $135.00
5/3/2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$84.00 ➝ $70.00
5/3/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSell ➝ Sell$65.00 ➝ $76.00
5/3/2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetMarket Outperform ➝ Market Outperform$114.00 ➝ $125.00
(Data available from 6/2/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$2.99B2.14$5.01 per share13.76$30.89 per share2.23
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
$249.38M26.51N/AN/A$4.96 per share21.28
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$3.73B1.85$5.75 per share21.10$27.82 per share4.36
HealthEquity, Inc. stock logo
HQY
HealthEquity
$999.59M7.11$3.42 per share23.89$23.72 per share3.44

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
-$21.67M-$0.14N/A17.572.01-0.38%11.49%6.07%7/25/2024 (Estimated)
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$506.98M-$4.81N/AN/AN/A-102.15%-193.48%-42.98%8/7/2024 (Estimated)
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$209.40M$3.8031.9122.211.635.67%17.60%6.33%7/25/2024 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$55.71M$0.64127.6329.281.205.57%6.91%4.41%6/3/2024 (Confirmed)

Latest ACHC, HQY, ENSG, and BPMC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2024N/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.6620N/A-$0.6620N/AN/AN/A  
5/2/2024Q1 2024
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
$0.80$0.84+$0.04$0.85$779.20 million$768.10 million    
5/2/2024Q1 2024
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
-$1.64-$1.32+$0.32-$4.04$82.58 million$96.12 million
5/1/2024Q1 2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$1.19$1.19N/A$1.19$1.01 billion$1.01 billion
3/19/2024Q4 2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.42$0.50+$0.08$0.70$258.56 million$262.39 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/AN/AN/AN/AN/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$0.240.20%+4.71%6.32%17 Years
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A

Latest ACHC, HQY, ENSG, and BPMC Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/22/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Quarterly$0.060.19%3/27/20243/31/20244/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
0.63
1.27
1.27
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
0.67
3.76
3.61
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.09
1.53
1.53
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.43
4.76
4.76

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
N/A
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
N/A
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
96.12%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%

Insider Ownership

CompanyInsider Ownership
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
2.00%
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
4.21%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
3.90%
HealthEquity, Inc. stock logo
HQY
HealthEquity
2.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Acadia Healthcare Company, Inc. stock logo
ACHC
Acadia Healthcare
23,50092.78 million90.92 millionOptionable
Blueprint Medicines Co. stock logo
BPMC
Blueprint Medicines
65562.62 million59.98 millionOptionable
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
35,30056.92 million54.70 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,15087.01 million85.10 millionOptionable

ACHC, HQY, ENSG, and BPMC Headlines

Recent News About These Companies

HealthEquity (HQY) to Release Quarterly Earnings on Monday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Acadia Healthcare logo

Acadia Healthcare

NASDAQ:ACHC
Acadia Healthcare Company, Inc. provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities. Acadia Healthcare Company, Inc. was founded in 2005 and is headquartered in Franklin, Tennessee.
Blueprint Medicines logo

Blueprint Medicines

NASDAQ:BPMC
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
The Ensign Group logo

The Ensign Group

NASDAQ:ENSG
The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
HealthEquity logo

HealthEquity

NASDAQ:HQY
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.